Ticker Launch
Sign inTry it free

SPAC · Deal announced · JATT

JATT II Acquisition Corp.

Business combination with Talawar Tx Inc.

JATT II Acquisition Corp. (JATT) is a blank-check company (SPAC) that raised $60M in its initial public offering on Apr 17, 2026, listing on Nasdaq Global Market. It agreed to combine with Talawar Tx Inc., announced on Jun 29, 2026, at a stated value of $120M. The deal has not closed yet. Athanor Capital led the IPO. Loeb & Loeb advised the SPAC and Davis Polk advised the underwriters on the IPO.

Talawar Tx Inc., operating as Talawar Therapeutics, is a biotechnology company developing bispecific antibodies for immunology and inflammatory diseases. Its lead program, TALA-125, is a bispecific antibody that targets both IL-13 and IL-18.

Status
Deal announced
Ticker
JATT
IPO date
Apr 17, 2026
IPO size
$60M
IPO exchange
Nasdaq Global Market
Target
Talawar Tx Inc. (Talawar Therapeutics)
Target sector
Biotech
Announced
Jun 29, 2026
Stated deal value
$120M
Combined company
Talawar Tx Inc.
IPO underwriters
Athanor Capital
SPAC counsel (IPO)
Loeb & Loeb and Appleby
Underwriters' counsel (IPO)
Davis Polk

More on this SPAC for subscribers

Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.

Try it free for 7 daysOpen in Ticker Launch

Then $99/month or $999/year. Cancel anytime.

Filings

Other pending SPAC mergers